Johnson & Johnson (JNJ:NYSE) closed at $263.81 on October 23, 2026, down 1.42% on the day. The stock trades 6.1% below its 52-week high of $281.07 and 42.9% above its 52-week low of $184.66. Over the past year, it gained 38.6%. Johnson & Johnson is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, JNJ closed higher on 132 days (52%). Its best day was June 26, 2026 (+3.99%) and its worst was October 13, 2026 (-5.73%). It never moved 10% or more in a single session.
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising brand adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and car...
Find more stocks like JNJ with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.